Top

Published in:

Open Access 01-12-2015 | Review

Granulocyte transfusions in children and adults with hematological malignancies: benefits and controversies

Authors: Chiara Cugno, Sara Deola, Perla Filippini, David F. Stroncek, Sergio Rutella

Published in: Journal of Translational Medicine | Issue 1/2015

Abstract

Bacterial and fungal infections continue to pose a major clinical challenge in patients with prolonged severe neutropenia after chemotherapy or hematopoietic stem cell transplantation (HSCT). With the advent of granulocyte colony-stimulating factor (G-CSF) to mobilize neutrophils in healthy donors, granulocyte transfusions have been broadly used to prevent and/or treat life-threatening infections in patients with severe febrile neutropenia and/or neutrophil dysfunction. Although the results of randomized controlled trials are inconclusive, there are suggestions from pilot and retrospective studies that granulocyte transfusions may benefit selected categories of patients. We will critically appraise the evidence related to the use of therapeutic granulocyte transfusions in children and adults, highlighting current controversies in the field and discussing complementary approaches to modulate phagocyte function in the host.

Chanock SJ, Gorlin JB. Granulocyte transfusions. Time for a second look. Infect Dis Clin North Am. 1996;10:327–43.CrossRefPubMed

Hubel K, Dale DC, Engert A, Liles WC. Use of G-CSF for granulocyte transfusion therapy. Cytokines Cell Mol Ther. 2000;6:89–95.CrossRefPubMed

Stroncek DF, Leitman SF. Granulocyte transfusions: a review. Immunohematology. 1998;14:101–8.PubMed

Huestis DW, Glasser L. The neutrophil in transfusion medicine. Transfusion. 1994;34:630–46.CrossRefPubMed

Vamvakas EC, Pineda AA. Determinants of the efficacy of prophylactic granulocyte transfusions: a meta-analysis. J Clin Apher. 1997;12:74–81.CrossRefPubMed

Dale DC, Price TH. Granulocyte transfusion therapy: a new era? Curr Opin Hematol. 2009;16:1–2.PubMedCentralCrossRefPubMed

Price TH. The use of G-CSF in normal neutrophil donors. Ann Med Interne (Paris). 2000;151:115–22.

Price TH. The current prospects for neutrophil transfusions for the treatment of granulocytopenic infected patients. Transfus Med Rev. 2000;14:2–11.CrossRefPubMed

Takahata M, Fukuhara T, Shigematsu A, Onozawa M, Yamamoto Y, Miyake T, Maekawa I. Successful treatment with allogeneic peripheral blood stem cell transplantation and granulocyte transfusion for severe aplastic anemia with sinusitis. Transpl Infect Dis. 2006;8:44–8.CrossRefPubMed

10.

Tsukada Y, Nagayama H, Mori T, Shimizu T, Sato N, Takayama N, Ishida A, Handa M, Ikeda Y, Okamoto S. Granulocyte transfusion as a treatment for enterococcal meningoencephalitis after allogeneic bone marrow transplantation from an unrelated donor. Bone Marrow Transplant. 2003;31:69–72.CrossRefPubMed

11.

Di Mario A, Sica S, Salutari P, Ortu La Barbera E, Marra R, Leone G. Granulocyte colony-stimulating factor-primed leukocyte transfusions in candida tropicalis fungemia in neutropenic patients. Haematologica. 1997;82:362–3.PubMed

12.

Safdar A, Rodriguez G, Zuniga J, Al Akhrass F, Pande A. Use of healthy-donor granulocyte transfusions to treat infections in neutropenic patients with myeloid or lymphoid neoplasms: experience in 74 patients treated with 373 granulocyte transfusions. Acta Haematol. 2014;131:50–8.PubMedCentralCrossRefPubMed

13.

McCullough J, Clay M, Herr G, Smith J, Stroncek D. Effects of granulocyte-colony-stimulating factor on potential normal granulocyte donors. Transfusion. 1999;39:1136–40.CrossRefPubMed

14.

Dale DC, Liles WC, Llewellyn C, Rodger E, Price TH. Neutrophil transfusions: kinetics and functions of neutrophils mobilized with granulocyte-colony-stimulating factor and dexamethasone. Transfusion. 1998;38:713–21.CrossRefPubMed

15.

Quillen K, Yau YY, Leitman SF. The determinants of granulocyte yield in 1198 granulocyte concentrates collected from unrelated volunteer donors mobilized with dexamethasone and granulocyte-colony-stimulating factor: a 13-year experience. Transfusion. 2009;49:421–6.PubMedCentralCrossRefPubMed

16.

Stroncek DF, Yau YY, Oblitas J, Leitman SF. Administration of G-CSF plus dexamethasone produces greater granulocyte concentrate yields while causing no more donor toxicity than G-CSF alone. Transfusion. 2001;41:1037–44.CrossRefPubMed

17.

Heuft HG, Goudeva L, Sel S, Blasczyk R. Equivalent mobilization and collection of granulocytes for transfusion after administration of glycosylated G-CSF (3 microg/kg) plus dexamethasone versus glycosylated G-CSF (12 microg/kg) alone. Transfusion. 2002;42:928–34.CrossRefPubMed

18.

Stroncek DF, Matthews CL, Follmann D, Leitman SF. Kinetics of G-CSF-induced granulocyte mobilization in healthy subjects: effects of route of administration and addition of dexamethasone. Transfusion. 2002;42:597–602.CrossRefPubMed

19.

Worel N, Kurz M, Peters C, Hocker P. Serial granulocytapheresis under daily administration of rHuG-CSF: effects on peripheral blood counts, collection efficiency, and yield. Transfusion. 2001;41:390–5.CrossRefPubMed

20.

de Haas M, Kerst JM, van der Schoot CE, Calafat J, Hack CE, Nuijens JH, Roos D, van Oers RH, von dem Borne AE. Granulocyte colony-stimulating factor administration to healthy volunteers: analysis of the immediate activating effects on circulating neutrophils. Blood. 1994;84:3885–94.PubMed

21.

Stroncek DF, Jaszcz W, Herr GP, Clay ME, McCullough J. Expression of neutrophil antigens after 10 days of granulocyte-colony-stimulating factor. Transfusion. 1998;38:663–8.CrossRefPubMed

22.

Rutella S, Pierelli L, Bonanno G, Sica S, Ameglio F, Capoluongo E, Mariotti A, Scambia G, d’Onofrio G, Leone G. Role for granulocyte colony-stimulating factor in the generation of human T regulatory type 1 cells. Blood. 2002;100:2562–71.CrossRefPubMed

23.

Drewniak A, van Raam BJ, Geissler J, Tool AT, Mook OR, van den Berg TK, Baas F, Kuijpers TW. Changes in gene expression of granulocytes during in vivo granulocyte colony-stimulating factor/dexamethasone mobilization for transfusion purposes. Blood. 2009;113:5979–98.CrossRefPubMed

24.

Drewniak A, Boelens JJ, Vrielink H, Tool AT, Bruin MC, van den Heuvel-Eibrink M, Ball L, van de Wetering MD, Roos D, Kuijpers TW. Granulocyte concentrates: prolonged functional capacity during storage in the presence of phenotypic changes. Haematologica. 2008;93:1058–67.CrossRefPubMed

25.

Buzzeo MP, Yang J, Casella G, Reddy V. Hematopoietic stem cell mobilization with G-CSF induces innate inflammation yet suppresses adaptive immune gene expression as revealed by microarray analysis. Exp Hematol. 2007;35:1456–65.CrossRefPubMed

26.

Massey E, Harding K, Kahan BC, Llewelyn C, Wynn R, Moppett J, Robinson SP, Green A, Lucas G, Sadani D, et al. The granulocytes in neutropenia 1 (GIN 1) study: a safety study of granulocytes collected from whole blood and stored in additive solution and plasma. Transfus Med. 2012;22:277–84.CrossRefPubMed

27.

Ikemoto J, Yoshihara S, Fujioka T, Ohtsuka Y, Fujita N, Kokubunji A, Okamoto N, Ono J, Taniguchi K, Kaida K, et al. Impact of the mobilization regimen and the harvesting technique on the granulocyte yield in healthy donors for granulocyte transfusion therapy. Transfusion. 2012;52:2646–52.CrossRefPubMed

28.

Cancelas JA, Padmanabhan A, Le T, Ambruso DR, Rugg N, Worsham DN, Pinkard SL, Graminske S, Buck J, Goldberg J, Bill J. Spectra Optia granulocyte apheresis collections result in higher collection efficiency of viable, functional neutrophils in a randomized, crossover, multicenter trial. Transfusion. 2014. doi:10.1111/trf.12907.

29.

Leitner GC, Kolovratova V, Horvath M, Worel N. Granulocyte collection using a novel apheresis system eases the procedure and provides concentrates of high quality. Transfusion. 2015;55:991–5.CrossRefPubMed

30.

Thorausch K, Schulz M, Bialleck H, Luxembourg B, Seifried E, Bonig H. Granulocyte collections: comparison of two apheresis systems. Transfusion. 2013;53:3262–8.CrossRefPubMed

31.

Chun H, Cipolone K, Procter J, Stroncek DF. Granulocyte storage and antigen stability. Transfusion. 1999;39:983–90.CrossRefPubMed

32.

Lightfoot T, Gallelli J, Matsuo K, Kwon SW, Leitman SF, Stroncek DF. Evaluation of solutions for the storage of granulocyte colony-stimulating factor-mobilized granulocyte concentrates. Vox Sang. 2001;80:106–11.CrossRefPubMed

33.

Lightfoot T, Leitman SF, Stroncek DF. Storage of G-CSF-mobilized granulocyte concentrates. Transfusion. 2000;40:1104–10.CrossRefPubMed

34.

Leavey PJ, Thurman G, Ambruso DR. Functional characteristics of neutrophils collected and stored after administration of G-CSF. Transfusion. 2000;40:414–9.CrossRefPubMed

35.

Hallahan AR, Shaw PJ, Rowell G, O’Connell A, Schell D, Gillis J. Improved outcomes of children with malignancy admitted to a pediatric intensive care unit. Crit Care Med. 2000;28:3718–21.CrossRefPubMed

36.

Liang DC. The role of colony-stimulating factors and granulocyte transfusion in treatment options for neutropenia in children with cancer. Paediatr Drugs. 2003;5:673–84.CrossRefPubMed

37.

Pham HP, Rogoza K, Stotler B, Duffy D, Parker-Jones S, Ginzburg Y, Bhatia M, Cairo M, Schwartz J. Granulocyte transfusion therapy in pediatric patients after hematopoietic stem cell transplantation: a 5-year single tertiary care center experience. J Pediatr Hematol Oncol. 2012;34:e332–6.CrossRefPubMed

38.

Diaz R, Soundar E, Hartman SK, Dreyer Z, Teruya J, Hui SK. Granulocyte transfusions for children with infection and neutropenia or granulocyte dysfunction. Pediatr Hematol Oncol. 2014;31:425–34.CrossRefPubMed

39.

Grigull L, Beilken A, Schmid H, Kirschner P, Sykora KW, Linderkamp C, Donnerstag F, Goudeva L, Heuft HG, Welte K. Secondary prophylaxis of invasive fungal infections with combination antifungal therapy and G-CSF-mobilized granulocyte transfusions in three children with hematological malignancies. Support Care Cancer. 2006;14:783–6.CrossRefPubMed

40.

Atay D, Ozturk G, Akcay A, Yanasik M, Anak S, Devecioglu O. Effect and safety of granulocyte transfusions in pediatric patients with febrile neutropenia or defective granulocyte functions. J Pediatr Hematol Oncol. 2011;33:e220–5.CrossRefPubMed

41.

Sachs UJ, Reiter A, Walter T, Bein G, Woessmann W. Safety and efficacy of therapeutic early onset granulocyte transfusions in pediatric patients with neutropenia and severe infections. Transfusion. 2006;46:1909–14.CrossRefPubMed

42.

Seidel MG, Minkov M, Witt V, Matthes-Martin S, Potschger U, Worel N, Leitner G, Stary J, Gadner H, Peters C. Granulocyte transfusions in children and young adults: does the dose matter? J Pediatr Hematol Oncol. 2009;31:166–72.CrossRefPubMed

43.

Cesaro S, Marson P, Messina C. Granulocyte-colony-stimulating factor-stimulated healthy donors and leukaemia risk. Vox Sang. 2003;85:125.CrossRefPubMed

44.

van de Wetering MD, Weggelaar N, Offringa M, Caron HN, Kuijpers TW. Granulocyte transfusions in neutropaenic children: a systematic review of the literature. Eur J Cancer. 2007;43:2082–92.CrossRefPubMed

45.

Peters C, Minkov M, Matthes-Martin S, Potschger U, Witt V, Mann G, Hocker P, Worel N, Stary J, Klingebiel T, Gadner H. Leucocyte transfusions from rhG-CSF or prednisolone stimulated donors for treatment of severe infections in immunocompromised neutropenic patients. Br J Haematol. 1999;106:689–96.CrossRefPubMed

46.

Hester JP, Dignani MC, Anaissie EJ, Kantarjian HM, O’Brien S, Freireich EJ. Collection and transfusion of granulocyte concentrates from donors primed with granulocyte stimulating factor and response of myelosuppressed patients with established infection. J Clin Apher. 1995;10:188–93.CrossRefPubMed

47.

Graham AS, Price TH, Brogan TV. Revisiting the use of granulocyte transfusions in pediatric oncology patients. J Pediatr Hematol Oncol. 2009;31:161–5.CrossRefPubMed

48.

Stanworth SJ, Massey E, Hyde C, Brunskill S, Lucas G, Navarrete C, Marks DI. Granulocyte transfusions for treating infections in patients with neutropenia or neutrophil dysfunction. Cochrane Database Syst Rev. 2005;(3):CD005339.

49.

Ikinciogullari A, Dogu F, Solaz N, Reisli I, Kemahli S, Cin S, Babacan E. Granulocyte transfusions in children with chronic granulomatous disease and invasive aspergillosis. Ther Apher Dial. 2005;9:137–41.CrossRefPubMed

50.

Sharon RF, Bierings M, Vrielink H, Versluys B, Boelens JJ. Pre-emptive granulocyte transfusions enable allogeneic hematopoietic stem cell transplantation in pediatric patients with chronic infections. Bone Marrow Transplant. 2006;37:331–3.CrossRefPubMed

51.

Lee JJ, Chung IJ, Park MR, Kook H, Hwang TJ, Ryang DW, Kim HJ. Clinical efficacy of granulocyte transfusion therapy in patients with neutropenia-related infections. Leukemia. 2001;15:203–7.CrossRefPubMed

52.

Price TH, Bowden RA, Boeckh M, Bux J, Nelson K, Liles WC, Dale DC. Phase I/II trial of neutrophil transfusions from donors stimulated with G-CSF and dexamethasone for treatment of patients with infections in hematopoietic stem cell transplantation. Blood. 2000;95:3302–9.PubMed

53.

Dignani MC, Anaissie EJ, Hester JP, O’Brien S, Vartivarian SE, Rex JH, Kantarjian H, Jendiroba DB, Lichtiger B, Andersson BS, Freireich EJ. Treatment of neutropenia-related fungal infections with granulocyte colony-stimulating factor-elicited white blood cell transfusions: a pilot study. Leukemia. 1997;11:1621–30.CrossRefPubMed

54.

Cherif H, Axdorph U, Kalin M, Bjorkholm M. Clinical experience of granulocyte transfusion in the management of neutropenic patients with haematological malignancies and severe infection. Scand J Infect Dis. 2013;45:112–6.CrossRefPubMed

55.

Mousset S, Hermann S, Klein SA, Bialleck H, Duchscherer M, Bomke B, Wassmann B, Bohme A, Hoelzer D, Martin H. Prophylactic and interventional granulocyte transfusions in patients with haematological malignancies and life-threatening infections during neutropenia. Ann Hematol. 2005;84:734–41.CrossRefPubMed

56.

Price TH (2014) The RING study: a randomized controlled trial of GCSF-stimulated granulocytes in granulocytopenic patients. ASH Annual Meeting Abstracts 124:SCI-16-SCI-16.

57.

Kadri SS, Remy KE, Strich JR, Gea-Banacloche J, Leitman SF. Role of granulocyte transfusions in invasive fusariosis: systematic review and single-center experience. Transfusion. 2015;55(9):2076–85.CrossRefPubMed

58.

Wang H, Wu Y, Fu R, Qu W, Ruan E, Wang G, Liu H, Song J, Xing L, Guan J, et al. Granulocyte transfusion combined with granulocyte colony stimulating factor in severe infection patients with severe aplastic anemia: a single center experience from China. PLoS One. 2014;9:e88148.PubMedCentralCrossRefPubMed

59.

Lee JJ, Song HC, Chung IJ, Bom HS, Cho D, Kim HJ. Clinical efficacy and prediction of response to granulocyte transfusion therapy for patients with neutropenia-related infections. Haematologica. 2004;89:632–3.PubMed

60.

Hubel K, Carter RA, Liles WC, Dale DC, Price TH, Bowden RA, Rowley SD, Chauncey TR, Bensinger WI, Boeckh M. Granulocyte transfusion therapy for infections in candidates and recipients of HPC transplantation: a comparative analysis of feasibility and outcome for community donors versus related donors. Transfusion. 2002;42:1414–21.CrossRefPubMed

61.

Metzendorf MI, Schulz M, Braun V. All information is not equal: using the literature databases PubMed and the Cochrane Library for identifying the evidence on granulocyte transfusion therapy. Transfus Med Hemother. 2014;41:364–74.PubMedCentralCrossRefPubMed

62.

Massey E, Paulus U, Doree C, Stanworth S. Granulocyte transfusions for preventing infections in patients with neutropenia or neutrophil dysfunction. Cochrane Database Syst Rev. 2015;6:CD005341. doi:10.1002/14651858.CD005341.pub3.

63.

Estcourt LJ, Stanworth S, Doree C, Blanco P, Hopewell S, Trivella M, Massey E. Granulocyte transfusions for preventing infections in people with neutropenia or neutrophil dysfunction. Cochrane Database Syst Rev. 2015;6:CD005341.PubMedCentralPubMed

64.

Stroncek DF, Leonard K, Eiber G, Malech HL, Gallin JI, Leitman SF. Alloimmunization after granulocyte transfusions. Transfusion. 1996;36:1009–15.CrossRefPubMed

65.

Heim KF, Fleisher TA, Stroncek DF, Holland SM, Gallin JI, Malech HL, Leitman SF. The relationship between alloimmunization and posttransfusion granulocyte survival: experience in a chronic granulomatous disease cohort. Transfusion. 2011;51:1154–62.PubMedCentralCrossRefPubMed

66.

Mannoni P, Rodet M, Vernant JP, Brun B, Coquin-Radeau EI, Bracq C, Rochant H, Dreyfus B. Efficiency of prophylactic granulocyte transfusions in preventing infections in acute leukaemia. Rev Fr Transfus Immunohematol. 1979;22:503–18.PubMed

67.

Gomez-Villagran JL, Torres-Gomez A, Gomez-Garcia P, Martinez-Guibelalde F, Velasco-Jimena F. A controlled trial of prophylactic granulocyte transfusions during induction chemotherapy for acute nonlymphoblastic leukemia. Cancer. 1984;54:734–8.CrossRefPubMed

68.

Clift RA, Sanders JE, Thomas ED, Williams B, Buckner CD. Granulocyte transfusions for the prevention of infection in patients receiving bone-marrow transplants. N Engl J Med. 1978;298:1052–7.CrossRefPubMed

69.

Anderlini P. Effects and safety of granulocyte colony-stimulating factor in healthy volunteers. Curr Opin Hematol. 2009;16:35–40.PubMedCentralCrossRefPubMed

70.

Rutella S, Rumi C, Pierelli L, Morosetti R, Sica S, Bonanno G, Scambia G, Leone G. Granulocyte colony-stimulating factor perturbs lymphocyte mitochondrial function and inhibits cell cycle progression. Exp Hematol. 2000;28:612–25.CrossRefPubMed

71.

Rutella S, Zavala F, Danese S, Kared H, Leone G. Granulocyte colony-stimulating factor: a novel mediator of T cell tolerance. J Immunol. 2005;175:7085–91.CrossRefPubMed

72.

Rutella S, Rumi C, Testa U, Sica S, Teofili L, Martucci R, Peschle C, Leone G. Inhibition of lymphocyte blastogenic response in healthy donors treated with recombinant human granulocyte colony-stimulating factor (rhG-CSF): possible role of lactoferrin and interleukin-1 receptor antagonist. Bone Marrow Transplant. 1997;20:355–64.CrossRefPubMed

73.

Shaw BE, Confer DL, Hwang W, Pulsipher MA. A review of the genetic and long-term effects of G-CSF injections in healthy donors: a reassuring lack of evidence for the development of haematological malignancies. Bone Marrow Transpl. 2015;50(3):334–40. doi:10.1038/bmt.2014.278.CrossRef

74.

Lyman GH, Dale DC. Long-term outcomes of myeloid growth factor treatment. J Natl Compr Canc Netw. 2011;9:945–52.PubMed

75.

Avalos BR, Lazaryan A, Copelan EA. Can G-CSF cause leukemia in hematopoietic stem cell donors? Biol Blood Marrow Transplant. 2011;17:1739–46.CrossRefPubMed

76.

Quillen K, Byrne P, Yau YY, Leitman SF. Ten-year follow-up of unrelated volunteer granulocyte donors who have received multiple cycles of granulocyte-colony-stimulating factor and dexamethasone. Transfusion. 2009;49:513–8.PubMedCentralCrossRefPubMed

77.

Olnes MJ, Poon A, Miranda SJ, Pfannes L, Tucker Z, Loeliger K, Padilla-Nash H, Yau YY, Ried T, Leitman SF, et al. Effects of granulocyte-colony-stimulating factor on monosomy 7 aneuploidy in healthy hematopoietic stem cell and granulocyte donors. Transfusion. 2012;52:537–41.PubMedCentralCrossRefPubMed

78.

Leitner GC, Faschingbauer M, Wenda S, Weigel G, Fischer G. Administration of recombinant human granulocyte-colony-stimulating factor does not induce long-lasting detectable epigenetic alterations in healthy donors. Transfusion. 2014;54:3121–6.CrossRefPubMed

79.

Marmier-Savet C, Larosa F, Legrand F, Witz B, Michallet M, Ranta D, Louvat P, Puyraveau M, Raus N, Tavernier M, et al. Persistence of lymphocyte function perturbations after granulocyte-colony-stimulating factor mobilization and cytapheresis in normal peripheral blood stem cell donors. Transfusion. 2010;50:2676–85.CrossRefPubMed

80.

De Silvestro G, Marson P, Cesaro S, Messina C. Legislative and ethical aspects of administering granulocyte colony-stimulating factor to normal donors. Haematologica. 2002;87:28–34.PubMed

81.

Vetillard J, Drouet M, Neildez-Nguyen TM, Mestries JC, Mathieu J, Thierry D, Herodin F. Interleukine-8 acts as a strong peripheral blood granulocyte-recruiting agent rather than as a hematopoietic progenitor cell-mobilizing factor. J Hematother Stem Cell Res. 1999;8:365–79.CrossRefPubMed

82.

Hubel K, Dale DC, Liles WC. Therapeutic use of cytokines to modulate phagocyte function for the treatment of infectious diseases: current status of granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, macrophage colony-stimulating factor, and interferon-gamma. J Infect Dis. 2002;185:1490–501.CrossRefPubMed

83.

Bodey GP, Anaissie E, Gutterman J, Vadhan-Raj S. Role of granulocyte-macrophage colony-stimulating factor as adjuvant treatment in neutropenic patients with bacterial and fungal infection. Eur J Clin Microbiol Infect Dis. 1994;13(Suppl 2):S18–22.CrossRefPubMed

84.

Nemunaitis J, Meyers JD, Buckner CD, Shannon-Dorcy K, Mori M, Shulman H, Bianco JA, Higano CS, Groves E, Storb R, et al. Phase I trial of recombinant human macrophage colony-stimulating factor in patients with invasive fungal infections. Blood. 1991;78:907–13.PubMed

85.

Nemunaitis J, Shannon-Dorcy K, Appelbaum FR, Meyers J, Owens A, Day R, Ando D, O’Neill C, Buckner D, Singer J. Long-term follow-up of patients with invasive fungal disease who received adjunctive therapy with recombinant human macrophage colony-stimulating factor. Blood. 1993;82:1422–7.PubMed

86.

Gallin J, Malech H, Melnick D. A controlled trial of interferon γ to prevent infection in chronic granulomatous disease. The International Chronic Granulomatous Disease Cooperative Study Group. N Engl J Med. 1991;324:509–16.CrossRef

87.

Safdar A, Rodriguez GH, Lichtiger B, Dickey BF, Kontoyiannis DP, Freireich EJ, Shpall EJ, Raad II, Kantarjian HM, Champlin RE. Recombinant interferon γ1b immune enhancement in 20 patients with hematologic malignancies and systemic opportunistic infections treated with donor granulocyte transfusions. Cancer. 2006;106:2664–71.CrossRefPubMed

88.

Li Y, Prasad A, Jia Y, Roy SG, Loison F, Mondal S, Kocjan P, Silberstein LE, Ding S, Luo HR. Pretreatment with phosphatase and tensin homolog deleted on chromosome 10 (PTEN) inhibitor SF1670 augments the efficacy of granulocyte transfusion in a clinically relevant mouse model. Blood. 2011;117:6702–13.PubMedCentralCrossRefPubMed

89.

Rutella S, Pierelli L, Sica S, Serafini R, Chiusolo P, Paladini U, Leone F, Zini G, D’Onofrio G, Leone G, Piccirillo N. Efficacy of granulocyte transfusions for neutropenia-related infections: retrospective analysis of predictive factors. Cytotherapy. 2003;5:19–30.CrossRefPubMed

90.

Kikuta A, Ohto H, Nemoto K, Mochizuki K, Sano H, Ito M, Suzuki H. Therapeutic transfusions of granulocytes collected by simple bag method for children with cancer and neutropenic infections: results of a single-centre pilot study. Vox Sang. 2006;91:70–6.CrossRefPubMed

91.

Ozturkmen S, Altuntas F, Olcay L. Granulocyte transfusion therapy in paediatric patients with severe neutropenic infection. Transfus Apher Sci. 2013;48:381–5.CrossRefPubMed

Title: Granulocyte transfusions in children and adults with hematological malignancies: benefits and controversies
Authors: Chiara Cugno
Sara Deola
Perla Filippini
David F. Stroncek
Sergio Rutella
Publication date: 01-12-2015
Publisher: BioMed Central
Published in: Journal of Translational Medicine / Issue 1/2015
Electronic ISSN: 1479-5876
DOI: https://doi.org/10.1186/s12967-015-0724-5

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Granulocyte transfusions in children and adults with hematological malignancies: benefits and controversies

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2015

Perspective of synaptic protection after post-infarction treatment with statins

Favorable in vitro effects of combined IL-12 and IL-18 treatment on NK cell cytotoxicity and CD25 receptor expression in metastatic melanoma patients

Milk: an epigenetic amplifier of FTO-mediated transcription? Implications for Western diseases

Mesenchymal stromal cells for cutaneous wound healing in a rabbit model: pre-clinical study applicable in the pediatric surgical setting

Identification of stroke-associated-antigens via screening of recombinant proteins from the human expression cDNA library (SEREX)

Evidence of IL-17, IP-10, and IL-10 involvement in multiple-organ dysfunction and IL-17 pathway in acute renal failure associated to Plasmodium falciparum malaria

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page